REPL

Replimune Group, Inc. - Common Stock (REPL)

About Replimune Group, Inc. - Common Stock (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$13.28

Daily low

$12.84

Price at open

$13.12

52 Week High

$16.33

52 Week Low

$1.50

Market cap

1.2B

Dividend yield

Volume

433,150

Avg. volume

2.1M

P/E ratio

-3.99

Replimune Group, Inc. - Common Stock News